中西医结合治疗抑郁障碍的临床证据总结
该研究基于ACE-iMed框架建立抑郁障碍专用数据库,纳入中药、针灸、艾灸和中医运动四类干预,检索至2025年9月6日,从41137条记录中分析1402项研究(RCT占87.9%)。结果显示中医治疗无论单用或联合常规西药均显示更优疗效和良好安全性,但证据尚需高质量研究验证。
要点
- 中医单用或联合西药治疗抑郁障碍均显示疗效增强和安全性良好。
- 证据库纳入1402项研究,其中RCT占87.9%,但方法学质量需提升。
- 结果基于ACE-iMed平台对8个临床问题的系统证据总结。
核心结论
- 中西医结合治疗抑郁障碍显示良好疗效和安全性,但需高质量研究验证以推动临床转化。
研究设计与样本
- 遵循ACE-iMed框架建立抑郁障碍专用数据库,纳入中药、针灸、艾灸和中医运动四类干预,针对8个临床问题系统检索筛选并严格评估方法学质量。
- 检索数据库和监管网站至2025年9月6日,纳入指南/共识、系统综述和随机对照试验。
- 从41137条初始记录中分析1402项研究,RCT占87.9%(n=1232)。
主要发现
- 中医治疗方式无论作为单药治疗还是与常规西药联合,对抑郁障碍均显示疗效增强和良好安全性。
- 全部8个临床问题的综合证据摘要已在ACE-iMed平台呈现,本研究重点展示CQ1和CQ7两个代表性临床问题。
临床怎么用
- 临床可考虑将中药、针灸、艾灸或中医运动作为抑郁障碍的单用或联合常规西药治疗选项,但需结合高质量证据进一步验证。
局限性
- 研究呼吁需要高质量研究验证现有发现并推动临床转化,提示当前证据方法学质量可能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite growing interest, evidence on integrated Chinese-Western medicine for depressive disorder (DD) remains fragmented, with no comprehensive summary across treatment modalities and evidence levels. Therefore, we summarized evidence to systematically delineate and visualize the scope, distribution, methodological quality, and results of clinical evidence on integrated Chinese-Western medicine for DD. METHODS: Adhering to the AI-empowered Clinical Evidence for Integrated Chinese-Western Medicine (ACE-iMed) framework, a dedicated database for DD was established. Four major categories of traditional Chinese medicine intervention were included, namely Chinese herbal medicine, acupuncture, moxibustion, and Chinese movement exercise. Eight clinical questions (CQs) with predefined outcomes were formulated, each undergoing a systematic process of targeted searching, screening, and rigorous methodological quality assessment. The search strategy involved comprehensive querying of databases and regulatory websites up to September 6, 2025. Eligible evidence types were restricted to clinical practice guidelines/consensus statements (CPGs/CSs), systematic reviews (SRs) and randomized controlled trials (RCTs). RESULTS: From an initial 41,137 records, 1402 studies were analyzed, with RCTs constituting the majority (n = 1232; 87.9%). While comprehensive evidence summaries for all eight CQs are presented on the ACE-iMed platform, this study focused on two representative CQs (CQ1 and CQ7). Overall, Chinese medicine treatment modalities, whether as monotherapy or in combination with conventional Western therapy, demonstrated enhanced efficacy and a favorable safety profile for DD. CONCLUSION: Using ACE-iMed, we summarized comprehensive evidence on integrated Chinese-Western medicine for DD, demonstrating favorable efficacy and safety and calling for high-quality studies to validate these findings and enable clinical translation in Hong Kong and beyond.
引用
- Yu DJ, Wu M, Tang HT, et al. Clinical evidence on integrated Chinese-Western medicine for depressive disorder. Integr Med Res. 2026. PMID: 42281904. doi:10.1016/j.imr.2026.101360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。